ADAP
Income statement / Annual
Last year (2024), Adaptimmune Therapeutics plc's total revenue was $178.03 M,
an increase of 195.34% from the previous year.
In 2024, Adaptimmune Therapeutics plc's net income was -$70.81 M.
See Adaptimmune Therapeutics plc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
06/30/2015 |
| Operating Revenue |
$178.03 M |
$60.28 M |
$27.15 M |
$6.15 M |
$3.96 M |
$1.12 M |
$59.51 M |
$37.83 M |
$14.20 M |
$10.72 M |
| Cost of Revenue |
$70,000.00
|
$9.86 M
|
$127.73 M
|
$111.09 M
|
$91.57 M
|
$97.50 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$177.96 M
|
$50.42 M
|
-$100.58 M
|
-$104.94 M
|
-$87.61 M
|
-$96.38 M
|
$59.51 M
|
$37.83 M
|
$14.20 M
|
$10.72 M
|
| Gross Profit Ratio |
1
|
0.84
|
-3.7
|
-17.07
|
-22.13
|
-85.9
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$149.06 M
|
$126.51 M
|
$127.73 M
|
$111.09 M
|
$91.57 M
|
$97.50 M
|
$98.27 M
|
$87.39 M
|
$63.79 M
|
$23.19 M
|
| General & Administrative Expenses |
$80.81 M
|
$71.81 M
|
$63.39 M
|
$57.31 M
|
$45.80 M
|
$43.39 M
|
$43.60 M
|
$31.11 M
|
$23.21 M
|
$11.32 M
|
| Selling & Marketing Expenses |
$506,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$81.31 M
|
$71.81 M
|
$63.39 M
|
$57.31 M
|
$45.80 M
|
$43.39 M
|
$43.60 M
|
$31.11 M
|
$23.21 M
|
$11.32 M
|
| Other Expenses |
$16.35 M
|
$0.00
|
-$536,000.00
|
$3.85 M
|
$1.16 M
|
$75,000.00
|
-$15.50 M
|
$8.74 M
|
$1.00 M
|
-$726,495.05
|
| Operating Expenses |
$246.72 M
|
$188.42 M
|
$191.11 M
|
$168.40 M
|
$137.36 M
|
$140.89 M
|
$141.87 M
|
$118.49 M
|
$87.00 M
|
$33.79 M
|
| Cost And Expenses |
$246.79 M
|
$198.28 M
|
$191.11 M
|
$168.40 M
|
$137.36 M
|
$140.89 M
|
$141.87 M
|
$118.49 M
|
$87.00 M
|
$33.79 M
|
| Interest Income |
$6.60 M
|
$5.96 M
|
$1.54 M
|
$1.10 M
|
$2.31 M
|
$2.77 M
|
$2.85 M
|
$2.23 M
|
$1.11 M
|
$787,000.00
|
| Interest Expense |
$3.35 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$376,000.00
|
$2.23 M
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$11.23 M
|
$9.84 M
|
$6.07 M
|
$6.57 M
|
$7.65 M
|
$8.04 M
|
$7.81 M
|
$5.42 M
|
$3.29 M
|
$732,785.00
|
| EBITDA |
-$52.67 M |
-$128.20 M |
-$155.59 M |
-$155.68 M |
-$125.81 M |
-$131.76 M |
-$74.56 M |
-$75.24 M |
-$69.51 M |
-$23.77 M |
| EBITDA Ratio |
-0.3
|
-2.13
|
-5.73
|
-25.32
|
-31.79
|
-117.43
|
-1.25
|
-1.99
|
-4.9
|
-2.22
|
| Operating Income Ratio |
-0.39
|
-2.29
|
-6.04
|
-26.39
|
-33.71
|
-124.57
|
-1.38
|
-2.13
|
-5.13
|
-2.15
|
| Total Other Income/Expenses Net |
$1.52 M
|
$25.50 M
|
-$1.29 M
|
$4.95 M
|
$3.48 M
|
$2.85 M
|
-$12.65 M
|
$10.97 M
|
$2.11 M
|
-$3.19 M
|
| Income Before Tax |
-$67.24 M
|
-$112.54 M
|
-$162.96 M
|
-$157.30 M
|
-$129.93 M
|
-$136.92 M
|
-$95.02 M
|
-$69.69 M
|
-$70.69 M
|
-$23.69 M
|
| Income Before Tax Ratio |
-0.38
|
-1.87
|
-6
|
-25.58
|
-32.83
|
-122.03
|
-1.6
|
-1.84
|
-4.98
|
-2.21
|
| Income Tax Expense |
$3.58 M
|
$1.34 M
|
$2.50 M
|
$791,000.00
|
$162,000.00
|
$242,000.00
|
$497,000.00
|
$451,000.00
|
$892,000.00
|
-$2.11 M
|
| Net Income |
-$70.81 M
|
-$113.87 M
|
-$165.46 M
|
-$158.09 M
|
-$130.09 M
|
-$137.17 M
|
-$95.51 M
|
-$70.14 M
|
-$71.58 M
|
-$21.59 M
|
| Net Income Ratio |
-0.4
|
-1.89
|
-6.09
|
-25.71
|
-32.87
|
-122.25
|
-1.61
|
-1.85
|
-5.04
|
-2.01
|
| EPS |
-0.28 |
-0.57 |
-1.02 |
-1.02 |
-0.9 |
-1.32 |
-0.96 |
-0.78 |
-1.02 |
-0.6 |
| EPS Diluted |
-0.28 |
-0.57 |
-1.02 |
-1.02 |
-0.9 |
-1.32 |
-0.96 |
-0.78 |
-1.02 |
-0.6 |
| Weighted Average Shares Out |
$252.30 M
|
$201.07 M
|
$161.21 M
|
$155.81 M
|
$142.46 M
|
$104.97 M
|
$97.39 M
|
$87.94 M
|
$70.79 M
|
$35.78 M
|
| Weighted Average Shares Out Diluted |
$252.30 M
|
$201.07 M
|
$161.21 M
|
$155.81 M
|
$142.46 M
|
$104.97 M
|
$97.39 M
|
$87.94 M
|
$70.79 M
|
$35.78 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
